Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Torben PlesnerHendrik-Tobias ArkenauFrancesca GayMonique C MinnemaMario BoccadoroPhillipe MoreauJamie CavenaghAurore PerrotJacob P LaubachJakub KrejcikTahamtan AhmadiCarla de BoerDiana ChenChristopher ChiuJordan M SchecterPaul Gerard RichardsonPublished in: British journal of haematology (2019)